Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Net Asset Momentum
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) recorded a net asset momentum of 31.8% as of December 2025, with net assets of $260.99 Million USD. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Check Contineum Therapeutics, Inc. Class A Com (CTNM) tangible net worth to evaluate the tangible quality of the company's equity base.
YoY Momentum
Current Net Assets
Years of Data
Country
Contineum Therapeutics, Inc. Class A Common Stock Net Asset Momentum (2021–2025)
This chart tracks Contineum Therapeutics, Inc. Class A Common Stock's year-over-year net asset growth across 5 annual reporting periods from 2021 to 2025. The most recent momentum reading is +31.8%, with net assets of $260.99 Million USD as of December 2025. Read debt load of Contineum Therapeutics, Inc. Class A Com for a breakdown of total debt and financial obligations.
Annual Net Asset History for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
The table below shows the complete annual net asset history for Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025, covering 5 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see CTNM company net worth.
| Year | Net Assets (USD) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | $260.99 Million | $276.64 Million | $15.65 Million | ▲ +31.8% |
| 2024 | $198.07 Million | $212.85 Million | $14.78 Million | ▲ +391.5% |
| 2023 | $-67.94 Million | $130.39 Million | $198.32 Million | ▼ -273.0% |
| 2022 | $39.27 Million | $50.64 Million | $11.37 Million | ▼ -36.2% |
| 2021 | $61.59 Million | $70.52 Million | $8.93 Million | — |